|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Diabetes increases the severity of impairment in PD, and GLP-1 improve it through its direct neuronal effect in addition to its indirect effect through producing hypoglycemia.
|
31654678 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1/hIgG2 was found to be effective in reducing the incidence of diabetes in multiple-low-dose streptozotocin-induced type 1 diabetes in mice.
|
20856794 |
2010 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 is a natural peptide possessing several actions that effectively combat diabetes.
|
21029027 |
2010 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GLP-1 release from alpha cells is upregulated in P. obesus during the development of diabetes.
|
21347622 |
2011 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 peptide agonists are efficacious drugs for the treatment of diabetes.
|
28562585 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 and GIP combination is suggested as a promising therapeutic strategy for treatment of obesity and diabetes.
|
28610922 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 analogues and SGLT-2 inhibitors are currently approved for use in diabetes, have shown early efficacy in NASH and also have beneficial cardiovascular effects.
|
28677333 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 was applied to treat the diabetic rats for one week after the onset of diabetes.
|
29104476 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 analogues are used in diabetes therapy.
|
29225158 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial cardiovascular or renal effects.
|
29247356 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 and GIP mimetics initially designed to treat diabetes show good protective effects in animal models of Alzheimer's and Parkinson's disease.
|
29402504 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1-based therapeutics have been highly successful in terms of obesity and diabetes management, however GIP therapies have found no clinical utility to date.
|
30028989 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 agonists are a candidate treatment in CF-related diabetes.
|
30259623 |
2019 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GLP-1 RA drugs in addition to conventional hypoglycemic therapy may significantly reduce systemic inflammation and circulating BNP levels in CRTd patients with diabetes, leading to a significant improvement of LVEF and of the 6 min walking test, and to a reduction of the arrhythmic burden.
|
30348145 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 agonists such as exenatide and liraglutide are novel drugs for the treatment of diabetes and obesity.
|
30906473 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 RAs and DPP-4 inhibitors show promise in the treatment of diabetes and obesity-related subfertility.
|
31260047 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 therapy is effective concerning weight loss in overweight patients and is more often used in females and patients with shorter diabetes duration.
|
31471633 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RAs are associated with a reduction in cardiovascular morbidity and mortality in high-risk patients with diabetes.
|
31595657 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1, a peptide hormone secreted from the gut stimulating insulin and suppressing glucagon secretion was identified as a parent compound for novel treatments of diabetes, but was degraded (dipeptidyl peptidase-4) eliminated (mainly kidneys) too fast (half-life 1-2 min) to be useful as a therapeutic agent.
|
31600725 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A single administration of rAd-GLP-1 via the tail vein into streptozotocin (STZ)-induced diabetic non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice resulted in remission of diabetes within 10 days; normoglycemia remained until the experiment was terminated.
|
17164779 |
2007 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although GLP-1 and GIP both enhance insulin secretion and subsequently ameliorate postprandial glucose excursion, most research has focused on GLP-1R as a therapeutic target for type 2 diabetes.
|
30637966 |
2019 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among them, 20 obese individuals with diabetes with inadequate glycemic control and metformin monotherapy received GLP-1Ra treatment for 3 months and were reassessed for metabolic, cognitive, olfactory, and neuroimaging changes.
|
31221697 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a sole treatment for diabetes and used with other hypoglycemic agents, it achieves a lowering of HbA1c of up to 1%, less than several competitor GLP-1 RAs.
|
27677385 |
2016 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As its glucose-lowering action is glucose dependent, a GLP-1 receptor agonist (GLP-1RA) achieves these benefits with a lower risk of hypoglycemia compared with other diabetes therapies.
|
28721686 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy.
|
31815785 |
2020 |